West Pharmaceutical Services (NYSE:WST) Stock Bumped Up to “Buy” by Wall Street Zen

Wall Street Zen upgraded shares of West Pharmaceutical Services (NYSE:WST) from a hold rating to a buy rating in a research report report published on Sunday,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on WST. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Evercore reaffirmed an “outperform” rating and issued a $425.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Citigroup lifted their price objective on shares of West Pharmaceutical Services from $412.00 to $494.00 and gave the stock a “buy” rating in a research report on Friday. Finally, TD Cowen upped their price target on West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a “buy” rating in a report on Friday. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $409.67.

West Pharmaceutical Services Trading Up 0.0%

Shares of WST stock opened at $412.73 on Friday. The stock has a fifty day simple moving average of $367.76 and a two-hundred day simple moving average of $313.21. The firm has a market capitalization of $28.75 billion, a PE ratio of 46.32, a PEG ratio of 2.73 and a beta of 1.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.10 and a current ratio of 2.82. West Pharmaceutical Services has a 52-week low of $223.83 and a 52-week high of $438.27.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.20 by $0.46. West Pharmaceutical Services had a net margin of 18.81% and a return on equity of 21.78%. The company had revenue of $874.50 million during the quarter, compared to the consensus estimate of $827.12 million. During the same quarter in the previous year, the firm posted $1.96 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, analysts predict that West Pharmaceutical Services will post 9.46 EPS for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th will be issued a dividend of $0.26 per share. The ex-dividend date is Tuesday, November 10th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.3%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s payout ratio is 9.88%.

Insider Buying and Selling

In other West Pharmaceutical Services news, VP Annette Favorite sold 2,524 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total transaction of $921,260.00. Following the completion of the transaction, the vice president owned 21,818 shares of the company’s stock, valued at $7,963,570. This represents a 10.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 15,659 shares of company stock worth $5,443,749. 0.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in West Pharmaceutical Services in the 2nd quarter worth $2,387,990,000. State Street Corp boosted its position in shares of West Pharmaceutical Services by 1.7% during the 2nd quarter. State Street Corp now owns 3,348,698 shares of the medical instruments supplier’s stock valued at $1,202,183,000 after acquiring an additional 54,920 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in West Pharmaceutical Services during the 2nd quarter worth approximately $733,733,000. Generation Investment Management LLP acquired a new position in shares of West Pharmaceutical Services during the second quarter worth about $728,168,000. Finally, Findlay Park Partners LLP acquired a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $214,196,000. Institutional investors own 93.90% of the company’s stock.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.